The use of methotrexate in conservative treatment of placenta accreta spectrum disorders. (12th December 2022)

• Record Type: Journal Article
• Authors: Gregoir, Caroline; De Becker, Ben; Hauspy, Jan; Vanderheyden, Tina; Loquet, Philip
• Is Part Of: Journal of maternal-fetal & neonatal medicine. Volume 35:Number 25(2022)
• Page Start: 7514
• Page End: 7517
• Publication Date: 2022-12-12
• Subjects: Conservative management -- methotrexate -- outcome -- placenta accreta spectrum disorder; Obstetrics -- Periodicals; Perinatology -- Periodicals; Infants (Newborn) -- Diseases -- Periodicals; Neonatology -- Periodicals; 618.2
• DOI: 10.1080/14767058.2021.1951211
• Languages: English
• ISSNs: 1476-7058

Abstract

Abstract: Aim of the study: This article reports on a series of patients with placenta accreta spectrum (PAS) disorder who were treated conservatively with Methotrexate (MTX) administration with or without embolization. We investigate whether there is a place for MTX in conservative treatment of PAS. Methods: We present a single-center retrospective case series of five patients. In all patients, diagnosis was unexpected and not made prenatally. Conclusion: The benefits should be weighed against the possible drug toxicity. Today high-quality evidence is lacking. PAS covers a broad spectrum of pathology, standardization in prenatal and postnatal diagnosis can help to compare evidence on treatment.